326 related articles for article (PubMed ID: 35359749)
1. Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates.
Cybula M; Bieniasz M
Oncotarget; 2022; 13():553-575. PubMed ID: 35359749
[TBL] [Abstract][Full Text] [Related]
2. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.
Liu JF; Palakurthi S; Zeng Q; Zhou S; Ivanova E; Huang W; Zervantonakis IK; Selfors LM; Shen Y; Pritchard CC; Zheng M; Adleff V; Papp E; Piao H; Novak M; Fotheringham S; Wulf GM; English J; Kirschmeier PT; Velculescu VE; Paweletz C; Mills GB; Livingston DM; Brugge JS; Matulonis UA; Drapkin R
Clin Cancer Res; 2017 Mar; 23(5):1263-1273. PubMed ID: 27573169
[No Abstract] [Full Text] [Related]
3. The latest animal models of ovarian cancer for novel drug discovery.
Magnotti E; Marasco WA
Expert Opin Drug Discov; 2018 Mar; 13(3):249-257. PubMed ID: 29338446
[TBL] [Abstract][Full Text] [Related]
4. Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.
Heo EJ; Cho YJ; Cho WC; Hong JE; Jeon HK; Oh DY; Choi YL; Song SY; Choi JJ; Bae DS; Lee YY; Choi CH; Kim TJ; Park WY; Kim BG; Lee JW
Cancer Res Treat; 2017 Oct; 49(4):915-926. PubMed ID: 28052650
[TBL] [Abstract][Full Text] [Related]
5. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
6. Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure.
Colombo PE; du Manoir S; Orsett B; Bras-Gonçalves R; Lambros MB; MacKay A; Nguyen TT; Boissière F; Pourquier D; Bibeau F; Reis-Filho JS; Theillet C
Oncotarget; 2015 Sep; 6(29):28327-40. PubMed ID: 26334103
[TBL] [Abstract][Full Text] [Related]
7. The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer.
Binder PS; Hashim YM; Cripe J; Buchanan T; Zamorano A; Vangveravong S; Mutch DG; Hawkins WG; Powell MA; Spitzer D
BMC Cancer; 2022 Mar; 22(1):263. PubMed ID: 35279106
[TBL] [Abstract][Full Text] [Related]
8. A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts.
Palmer AC; Plana D; Gao H; Korn JM; Yang G; Green J; Zhang X; Velazquez R; McLaughlin ME; Ruddy DA; Kowal C; Muszynski J; Bullock C; Rivera S; Rakiec DP; Elliott G; Fordjour P; Meyer R; Loo A; Kurth E; Engelman JA; Bitter H; Sellers WR; Williams JA; Sorger PK
Cancer Res; 2020 Oct; 80(19):4278-4287. PubMed ID: 32747364
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
10. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
11. Molecular and clinical implementations of ovarian cancer mouse avatar models.
Zayed AA; Mandrekar SJ; Haluska P
Chin Clin Oncol; 2015 Sep; 4(3):30. PubMed ID: 26408297
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of an ovarian yolk sac tumor patient-derived xenograft model.
Luo M; He Y; Xie B; Li S; Gan F; Zhang S; Luo P
Pediatr Surg Int; 2021 Aug; 37(8):1031-1040. PubMed ID: 34031745
[TBL] [Abstract][Full Text] [Related]
13. Correlation between expression of oncogene products and resistance to anticancer drugs in cultured ovarian cancer cell lines.
Okuma Y; Kiguchi K; Koshitaka Y; Okamura A; Ishiwata I; Kondo H; Ishizuka B; Tadokoro M
Hum Cell; 2003 Sep; 16(3):131-9. PubMed ID: 15005244
[TBL] [Abstract][Full Text] [Related]
14. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
[TBL] [Abstract][Full Text] [Related]
15. Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.
Ciucci A; Buttarelli M; Fagotti A; Scambia G; Gallo D
Cell Mol Life Sci; 2022 Jun; 79(7):364. PubMed ID: 35705879
[TBL] [Abstract][Full Text] [Related]
16. Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer.
Capellero S; Erriquez J; Melano C; Mesiano G; Genta S; Pisacane A; Mittica G; Ghisoni E; Olivero M; Di Renzo MF; Aglietta M; Sangiolo D; Valabrega G
Sci Rep; 2020 Apr; 10(1):6478. PubMed ID: 32296104
[TBL] [Abstract][Full Text] [Related]
17. Harnessing preclinical models for the interrogation of ovarian cancer.
Qin T; Fan J; Lu F; Zhang L; Liu C; Xiong Q; Zhao Y; Chen G; Sun C
J Exp Clin Cancer Res; 2022 Sep; 41(1):277. PubMed ID: 36114548
[TBL] [Abstract][Full Text] [Related]
18. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
[TBL] [Abstract][Full Text] [Related]
19. Applications of patient-derived tumor xenograft models and tumor organoids.
Yoshida GJ
J Hematol Oncol; 2020 Jan; 13(1):4. PubMed ID: 31910904
[TBL] [Abstract][Full Text] [Related]
20. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers.
Peng S; Creighton CJ; Zhang Y; Sen B; Mazumdar T; Myers JN; Lai SY; Woolfson A; Lorenzi MV; Bell D; Williams MD; Johnson FM
J Transl Med; 2013 Aug; 11():198. PubMed ID: 23981300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
